-
Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
11 Apr 2024 16:52 GMT
… for non-small-cell lung cancer (NSCLC) patients ineligible … 7,8 of all lung cancers cases, with nearly … the specific proportion of gemcitabine and vinorelbine usage. Consequently … -cell lung cancer: a cost-effectiveness analysis. Translational Lung Cancer Res. …
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
05 Apr 2024 11:50 GMT
… cell lung cancer (ES-SCLC).
IMFINZI, in combination with gemcitabine and … .
Notes
Small cell lung cancer
Lung cancer is the leading cause … IMFINZI in liver and lung cancers, the combination of … caregivers/lung-cancer-101/types-of-lung-cancer. Accessed …
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
05 Apr 2024 11:27 GMT
… cell lung cancer (ES-SCLC).
IMFINZI, in combination with gemcitabine and … .
Notes
Small cell lung cancer
Lung cancer is the leading cause … IMFINZI in liver and lung cancers, the combination of … caregivers/lung-cancer-101/types-of-lung-cancer. Accessed …
-
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
04 Apr 2024 11:01 GMT
… non-small cell lung cancers (adenocarcinoma). Despite … been challenging.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … protein-bound, or gemcitabine and carboplatin) were …
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
28 Mar 2024 11:00 GMT
… patients with metastatic lung cancer, lung cancer continues to … cycles.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … protein-bound, or gemcitabine and carboplatin) were …
-
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
21 Mar 2024 11:01 GMT
… non-small cell lung cancer. We sincerely thank … intolerable toxicity.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … in combination with gemcitabine and cisplatin, KEYTRUDA …
-
Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 8, Status: Authorised
18 Apr 2024 16:54 GMT
… or recurrent non small cell lung cancer other than predominantly squamous cell … non squamous non small cell lung cancer with Epidermal Growth Factor Receptor … , in combination with carboplatin and gemcitabine or in combination with carboplatin …
-
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
04 Mar 2024 10:29 GMT
… nonsquamous non-small cell lung cancer (NSCLC) who … , capecitabine, vinorelbine or gemcitabine) in patients with unresectable … Small Cell Lung Cancer
Nearly 500,000 lung cancer cases were … References:
1 Cancer.net. Lung Cancer – Non-Small Cell: Statistics …
-
Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials
18 Apr 2024 07:34 GMT
… PDAC patients previously treated with gemcitabine-based therapies (median overall … in non small cell lung cancer. Both are small molecules … in non-small cell lung cancer, in the context of … pathways: targeting NRG1 fusions in lung cancer. Clin Cancer Res. 2015 …
-
Paclitaxel albumin bound by Bristol-Myers Squibb for Gallbladder Cancer: Likelihood of Approval
18 Apr 2024 03:41 GMT
… or metastatic non-small cell lung cancer (NSCLC), as first-line treatment … -line treatment, in combination with gemcitabine.
It is under development for … cell lung cancer, HER2 positive breast cancer, small cell lung cancer, non-small cell lung cancer …